

## Ξένες δημοσιεύσεις

---

- 1. Prognostic significance of autoantibodies against tropomyosin in patients with colorectal adenocarcinoma. Syrigos KN, Charalambopoulos A, **Pliarchopoulou K**, Syrigou EI, Avuzuklidou M, Manouras A, Leandros M. *Hybridoma* 1999;18(6): 543-6
- 2. The prognostic significance of autoantibodies against ds- DNA in patients with colorectal adenocarcinoma. Syrigos KN, Charalambopoulos A, **Pliarchopoulou K**, Varsamidakis N, Machairas A, Mandrekas D. *Anticancer Res* 2000;20 (6B):4351-3 (IF:1,416)
- 3. The development of monoclonal antibody therapy in leukemias. Syrigos KN, **Pliarchopoulou K**, Harrington KJ. *Hybridoma* 2001; 20(3):145-148
- 4. Parallel morning and evening surges in stroke onset, blood pressure and physical activity. Stergiou GS, Vemmos KN, **Pliarchopoulou KM**, Synetos AG, Roussias LG, Mountokalakis TD. *Stroke* 2002;33(6):1480-6
- 5. Pancreatic cancer: current and future treatment strategies. **K.Pliarchopoulou**, D. Pectasides. *Cancer Treat Rev* 2009;35(5):431-6 (IF:4,729)
- 6. First-line chemotherapy of non-seminomatous germ cell tumors (NSGCTs). **K.Pliarchopoulou**, D.Pectasides. *Cancer Treat Rev* 2009; 35(7):563-9 (IF:4,729)
- 7. Primary fallopian tube carcinoma:results of a retrospective analysis of 64 patients. Pectasides D, Pectasides E, Papaxoinis G, Andreadis C, Papatsibas G, Fountzilias G, **Pliarchopoulou K**, Macheras A, Aravantinos G, Economopoulos T. *Gynecol Oncol* 2009;115(1):97-101 (IF:2,919)
- 8. Gastric metastases originating from breast cancer: report of 8 cases and review of the literature. Pectasides D, Psyrri A, **Pliarchopoulou K**, Floros T, Papaxoinis G, Skondra M, Papatsibas G, Macheras A, Athanasas G, Arapantoni-Datioti P, Economopoulos T. *Anticancer Res* 2009;29(11):4759-63 (IF:1,416)
- 9. Late complications of chemotherapy in testicular cancer. **K. Pliarchopoulou**, D. Pectasides. *Cancer Treat Rev* 2010;36(3): 262-7 (IF:4,729)
- 10. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/ resistant paclitaxel-pretreated ovarian carcinoma. Pectasides D, Pectasides E, Papaxoinis G, Psyrri A, **Pliarchopoulou K**, Koumariou A, Macheras A, Athanasas G, Xiros N, Economopoulos T. *Gynecol Oncol* 2010; 118(1):52-7. (IF:2,919)
- 11. Epithelial ovarian cancer: focus on targeted therapy. **K. Pliarchopoulou**, D. Pectasides. *Crit Rev Oncol Hematol* 2011; 79(1):17-23 (IF: 5,269)
- 12. Current chemotherapeutic options for the treatment of advanced bladder cancer: a review. **K.Pliarchopoulou**, **K. Laschos**, **D. Pectasides**. *Urol Oncol* 2013; 31(3):294-302 (IF: 2,531)
- 13. Chronic myelogenous leukemia and colon cancer: a causal relationship or coincidence? Kanellopoulou T, Kontopidou FN, Skondra M, **Pliarchopoulou K**, Pectasides D. *Ann Gastroenterol.* 2011; 24(2):140-141.
- 14. Correlation of CYP1A1, GSTP1, GSTM1 gene polymorphisms and lung cancer risk among smokers in a Greek population. **K. Pliarchopoulou**, Gerasimos Voutsinas, George Papaxoinis, Katherine Florou, Maria Skondra, Konstantina Kostaki, Paraskevi Roussou, Konstantinos Syrigos, Dimitrios Pectasides. *Oncol Lett* 2012; 3(6):1301-1306

- 15. Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. [Pliarchopoulou K](#), [Kalogeras KT](#), [Kronenwett R](#), [Wirtz RM](#), [Eleftheraki AG](#), [Batistatou A](#), [Bobos M](#), [Soupos N](#), [Polychronidou G](#), [Gogas H](#), [Samantas E](#), [Christodoulou C](#), [Makatsoris T](#), [Pavlidis N](#), [Pectasides D](#), [Fountzilias G](#). *Cancer Chemother Pharmacol* 2013;71(1):245-55
- 16. Metastatic cardiac sarcoma arising from the left posterior pulmonary vein treated with combination therapy of surgical resection and preoperative chemotherapy treatment. Aggeli C, Kastellanos S, **Pliarchopoulou K**, Felekos I, Stefanadis C. *Echocardiography*. 2015 Jan;32(1):187-8